drugset / Trial / NCT06973005

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

NCT06973005

Phase 1 Completed 16 enrolled AstraZeneca Parexel · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the effect of multiple doses of AZD2389 on the pharmacokinetics (PK) of midazolam, caffeine, and bupropion in healthy participants.

Timeline

Start
2025-05-08
Primary completion
2025-07-18
Completion
2025-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2389 Small molecule Oral
Subject Bupropion Small molecule Oral
Subject Caffeine Small molecule Oral
Subject Midazolam Small molecule Oral

Indications